Baxter (NYSE:BAX) Canada announced today that it received Health Canada authorization for its Novum IQ infusion platform.
Novum IQ received marketing authorization for its large volume pump and syringe infusion pumps, as well as Mississauga, Ontario-based Baxter Canada’s Dose IQ safety software. Baxter expects Novum IQ to be available to Canadian customers in the coming weeks, according to a news release.
“We are excited to introduce Novum IQ, our newest infusion pump platform designed to provide personalized therapy and help prevent harm to patients.” Baxter Canada head of medication delivery Anne-Marie Carli said in the release. “The integrated platform provides for both large volumetric and syringe infusion pumps adding another option for Canadian hospitals to provide high-quality infusion therapy for patients. Novum IQ is a full-suite package offered in both English and French.”
Baxter’s Dose IQ safety software is a web-based, customizable drug library and dose error reduction system which operates to assist clinicians in reducing the occurrence of potential dosing errors.
With Dose IQ as part of the Novum IQ system, Baxter’s newly approved product fully integrates with hospital electronic medical records and can differentiate enteral delivery on the syringe pump through designated screen colors.
Additionally, it offers over-the-air drug library and software updates for all pumps connected to a hospital’s network and provides clear visualizations of infusion data across a hospital system for efficient identification of safety and process issues at every level.
